Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nidek v. Visx

This article was originally published in The Gray Sheet

Executive Summary

Nidek is now permitted to recommence action in its antitrust allegations against Visx following U.S. District Court Judge Charles Breyer's decision to lift a stay currently in place on the case. Judge Breyer's decision follows a Dec. 6 ruling by International Trade Commission Administrative Law Judge Debra Morriss that Nidek does not infringe two Visx LASIK patents covering the apparatus and method for performing the ophthalmic surgical procedure (1"The Gray Sheet" Dec. 13, p. 15)

You may also be interested in...



Visx v. Nidek ITC LASIK Ruling May Open Door For Bausch & Lomb, Others

A recent ruling by the International Trade Commission weakens, at least temporarily, the patent position of Visx and co-licensor Summit Technology in the rapidly growing laser-assisted in situ keratomileusis (LASIK) market, and creates an opening for a formidable competitor, Bausch & Lomb, whose Technolas LASIK device awaits FDA approval.

FDA Overhauls Its Purple Book

The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.

ICH Syncs Reproductive Toxicity Guidance With Current Science

The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.

UsernamePublicRestriction

Register

MT012747

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel